Skip to main content

Table 2 Genes with two-fold or greater (p < 0.05) differential expression after pioglitazone treatment.

From: Pioglitazone administration alters ovarian gene expression in aging obese lethal yellow mice

Accession #

Δ1 (pioglitazone)

Δ2 (C57BL/6J)

Gene name

NM_008493.3

0.28

0.17

leptin (Lep)

NM_009640.2

0.35

0.65

angiopoietin (Agpt)

NM_177839.2

0.44

0.61

tenascin N (Tnn)

CF906297.1

0.46

0.37

formyltetrahydrofolate synthetase domain 1

AK083494.1

0.46

0.72

ubiquitin specific protease 29

NM_008260.1

0.47

0.54

forkhead box A3 (Foxa3)

CK329907.1

0.49

0.45

aconitase 2, mitochondrial

AK005115.1

0.50

0.85

zinc-finger RNA-binding domain containing 1

NM_025914.1

0.50

0.65

actin-related protein 6 homolog, ARP6

NM_020581.1

0.50

0.88

angiopoietin-like 4 (Angptl4)

NM_008962.2

2.00

2.54

prostaglandin D receptor (Ptgdr)

NM_178779.2

2.00

2.40

ring finger protein 152

BC025027.1

2.00

1.59

similar to phospholipase C, epsilon

NM_021462.2

2.02

1.92

MAP kinase-interacting ser/thr kinase 2

NM_134249.3

2.04

2.05

T-cell immunoglobulin/mucin domain 2 (Timd2)

NM_011904.1

2.05

1.84

tolloid-like 2 (Tll2)

AK053616.1

2.07

1.77

prostaglandin E receptor 1

NM_009188.1

2.08

2.52

transcriptional regulator, SIN3B (Sin3b)

BY482739.1

2.08

1.54

membrane associated guanylate kinase interacting-1

AI604236.1

2.32

1.50

E74-like factor 1

NM_021447.1

2.50

2.05

ring finger protein 30 (Rnf30)

NM_020509.2

2.62

1.04

resistin-like alpha (RELMα)

NM_008830.1

2.82

2.18

ATP-binding cassette, subfamily B, member 4

NM_148937.1

3.33

1.81

phospholipase Cδ 4

AF223416.1

3.55

1.85

cardiac triadin isoform 2 mRNA

NM_198864.2

3.58

1.91

SLIT and NTRK-like family, member 3 (Slitrk3)

BB393194.2

5.22

0.84

dipeptidylpeptidase 10

  1. Vehicle-treated LY mice (controls) were assigned a level of expression of 1.0 for each gene Relative expression of pioglitazone-treated LY mice (Δ1) and untreated BL non-mutant mice (Δ2) compared with control mice is expressed as the fold-difference of the mean level of expression of four (vehicle- and pioglitazone-treated) or two (untreated C57BL/6J) animals per group.